- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Gwreiddiol (a wnaed Fel)
The Human Medicines Regulations 2012, PART 1 is up to date with all changes known to be in force on or before 06 September 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.
Whole provisions yet to be inserted into this Instrument (including any effects on those provisions):
1. The name of the medicinal product.U.K.
2. The strength and pharmaceutical form of the product.U.K.
3. Where appropriate, whether the product is intended for babies, children or adults.U.K.
4. Where the product contains up to three active substances, the common name of each active substance.U.K.
5. The pharmaco-therapeutic group, or type of activity, of the product, in terms easily comprehensible for the patient.U.K.
6. The product's therapeutic indications.U.K.
7. A list of—U.K.
(a)contra-indications;
(b)appropriate precautions for use;
(c)interactions with other medicinal products which may affect the action of the product;
(d)interactions with other substances, including alcohol, tobacco and foodstuffs, which may affect the action of the product; and
(e)special warnings, if any, relating to the product.
8. The list mentioned in paragraph 7 must—U.K.
(a)take into account the special requirements of particular categories of users (including, in particular, children, pregnant or breastfeeding women, the elderly and persons with specific pathological conditions);
(b)mention, if appropriate, possible effects on the ability to drive vehicles or to operate machinery; and
(c)list any excipients—
(i)if knowledge of the excipients is important for the safe and effective use of the product, and
(ii)the excipients are included in the guidance published pursuant to [F1published under regulation 257D in the case of products for sale or supply in Great Britain, or in the case of products for sale or supply in Northern Ireland, any guidance published pursuant to Article 65 of the 2001 Directive or under regulation 257D that is applicable to such products.]
Textual Amendments
F1Words in Sch. 27 para. 8(c)(ii) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(2) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(a)); 2020 c. 1, Sch. 5 para. 1(1)
9. Instructions for proper use of the product including in particular—U.K.
(a)the dosage;
(b)the method and, if necessary, route of administration;
(c)the frequency of administration (including, if necessary, specifying times at which the product may or must be administered);
(d)the duration of treatment if this is to be limited;
(e)symptoms of an overdose and the action, if any, to be taken in case of an overdose;
(f)what to do if one or more doses have not been taken;
(g)an indication, if necessary, of the risk of withdrawal effects; and
(h)a specific recommendation to consult a doctor or pharmacist, as appropriate, for further explanation of the use of the product.
10. A description of the adverse reactions which may occur in normal use of the medicinal product and, if necessary, the action to be taken in such a case.U.K.
11. A reference to the expiry date printed on the packaging of the product with—U.K.
(a)a warning against using the product after that date;
(b)if appropriate, details of special storage precautions to be taken;
(c)if necessary, a warning concerning visible signs of deterioration;
(d)the full qualitative composition (in active substances and excipients), and the quantitative composition in active substances, using common names, of each presentation of the medicinal product;
(e)for each presentation of the product, the pharmaceutical form and content in weight, volume or units of dosage;
(f)the name and address of the holder of the [F2UK marketing authorisation, EU marketing authorisation], Article 126a authorisation or traditional herbal registration relating to the product and, if applicable, the name of the holder's appointed representative; and
(g)the name and address of the manufacturer of the product.
Textual Amendments
F2Words in Sch. 27 para. 11(f) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, reg. 204(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(b)); 2020 c. 1, Sch. 5 para. 1(1)
12. Where the product [F3is authorised for sale or supply in Northern Ireland and] is authorised under different names in different member States in accordance with Articles 28 to 39 of the 2001 Directive, a list of the names authorised in each member State.U.K.
Textual Amendments
F3Words in Sch. 27 para. 12 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(4) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(c)); 2020 c. 1, Sch. 5 para. 1(1)
13. For medicinal products included in the list referred to in Article 23 of Regulation (EC) No 726/2004 [F4in the case of products for sale or supply in Northern Ireland, or the list referred to in regulation 202A, in the case of products for sale or supply in Great Britain,] the [F5symbol and ] statement: “[F6▼] This medicinal product is subject to additional F7... monitoring”.U.K.
Textual Amendments
F4Words in Sch. 27 para. 13 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(5)(a) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(d)); 2020 c. 1, Sch. 5 para. 1(1)
F5Words in Sch. 27 para. 13 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(5)(b); 2020 c. 1, Sch. 5 para. 1(1)
F6Symbol in Sch. 27 para. 13 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(5)(c); 2020 c. 1, Sch. 5 para. 1(1)
F7Word in Sch. 27 para. 13 omitted (E.W.S.) (1.10.2014) by virtue of The Human Medicines (Amendment) (No. 2) Regulations 2014 (S.I. 2014/1878), regs. 1, 28(2) and word in Sch. 27 para. 13 omitted (N.I.) (1.10.2014) by virtue of The Human Medicines (Amendment) (No. 2) Regulations 2014 (S.R. 2014/324), regs. 1(1), 28(2)
[F814. A standardised text relating to adverse event reporting in accordance with the third sub-paragraph of Article 59(1) of the 2001 Directive.]U.K.
Textual Amendments
F8Sch. 27 para. 14 substituted (E.W.S.) (1.10.2014) by The Human Medicines (Amendment) (No. 2) Regulations 2014 (S.I. 2014/1878), regs. 1, 28(3) and Sch. 27 para. 14 substituted (N.I.) (1.10.2014) by The Human Medicines (Amendment) (No. 2) Regulations 2014 (S.R. 2014/324), regs. 1(1), 28(3)
15. The date on which the package leaflet was last revised.U.K.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
Yr Offeryn Cyfan you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Yr Offeryn Cyfan heb Atodlenni you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Rhestrau you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys